Chewable tablet for diabetes a step closer to FDA approval

from the New Hampshire Union Leader:

MANCHESTER — Boston Therapeutics, a pharmaceutical research and development firm, is one step closer to FDA approval for a chewable version of a widely used generic to treat diabetic or pre-diabetic patients.

The company announced Thursday that the FDA has authorized an abbreviated new drug application, which means no further clinical trials are needed to demonstrate the safety or effectiveness of the product.

Read more.